Bioxytran Reports Positive Phase 2 Results for ProLectin-M, Demonstrating 100% Viral Clearance
BIXT sits 38% above its 52-week low of $0.034.
Summary
Bioxytran reported compelling positive Phase 2 clinical trial results for ProLectin-M, showing 100% viral clearance by Day 7 in treated subjects, paving the way for late-stage development.
Key Events · Product Development and Regulatory · BIXT
-
Positive Phase 2 Results for ProLectin-M
Bioxytran announced successful completion of its Phase 2 randomized, double-blind, placebo-controlled trial for ProLectin-M in acute viral infection.
-
100% Viral Clearance Achieved
The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7, a statistically significant outcome (p = .001) compared to the placebo group.
-
Rapid and Sustained Clearance
Results indicated rapid viral clearance, with a significant proportion of treated subjects achieving viral non-detection by Day 3 and no viral rebounds during a 14-day post-treatment observation period.
-
Novel Mechanism of Action
ProLectin-M's galectin antagonist mechanism interferes with viral entry at the cell surface, representing a fundamentally different strategy in antiviral therapy.
Analysis · BIXT · Life Sciences
Bioxytran, a clinical-stage biotechnology company, announced highly positive Phase 2 clinical trial results for its lead antiviral therapeutic, ProLectin-M. The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7, a statistically significant outcome compared to placebo (p = .001). This strong data significantly de-risks the drug's development, validating its novel mechanism of action which interferes with viral entry at the cell surface. The company plans to advance regulatory discussions for late-stage clinical development, which is a critical step towards potential commercialization and could be transformative for this micro-cap biotech.
At the time of this filing, BIXT was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.03 to $0.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.